MENA Biologics & Biosimilars Market, by Product Type (Influenza Vaccines, Factor VIII, (Octanate, Novoeight, Kovaltry, Koate, Immunate, Adynovate, Hemlibra, Recombinate, Elocta, Kogenate, Feiba, Alphanate, Advate, and Xyntha), Erythropoietin (Epoetin Alfa (Binocrit (4000IU & 2000IU) (Eprex (4000IU & 2000IU) Aranesp (Darbepoietin Alfa) and Epoetin Alfa-epbx (Recormon & Retacrit)), EYLEA (Aflibercept), and ZALTRAP (Ziv-Aflibercept)), by Therapeutic Application (Influenza, Kidney Diseases, Hemophilia, and Age-related Macular Degeneration), and by Nation/Territory (Egypt & Gulf), had a valuation of US$ 442.5 million in 2021 and is anticipated to grow at a CAGR of 3.9 percent over the forecast period (2022-2028), as mentioned in a new report published by Coherent Market Insights.
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
Recently, a few novel biopharmaceutical items have been supported by major administrative bodies, the Ministry of Wellbeing, and key players in the market have introduced different novel and creative biopharmaceutical items. Fast endorsements and dispatches of novel items in the market are projected to drive the development of the MENA biologics & biosimilars market.
In 2016, Baxalta Incorporated created ADYNOVATE, an antihemophilic recombinant variable shown for patients over 12 years experiencing Hemophilia A. It is accessible in Kuwait, Saudi Arabia, and another 65 nations all around the world.
In 2016, the Ministry of Health in Kuwait supported the development of efmoroctocog alfa (Elocta), a recombinant human element VIII Fc-combination protein for the treatment of hemophilia A.
Effect of the Coronavirus (Covid-19) Pandemic
The COVID-19 pandemic and lockdowns in different nations across the globe have affected the monetary status of organizations in all areas. The private medical services area is one of the areas that is significantly affected by the COVID-19 pandemic. The Saudi Arabian government, worldwide drug organizations, and nearby producers are carrying out different procedures to help the occupants of Saudi Arabia during this COVID-19 pandemic.
In April 2020, Saudi Arabia’s National Unified Procurement Company (NUPCO) and a Chinese organization, ‘Huo-yan Laboratories’- COVID-19 testing labs created by the Chinese genomics group, BGI Group, consented to a participation arrangement in Riyadh to assemble six significant research facilities, including a versatile lab to build the country’s Covid testing limit. In the wake of getting done, the research centers would provide neighborhood COVID testing ability to 50,000 individuals each day and give 9 million testing packs.
Request PDF Brochure with Latest Insights @
In April 2020, the Ministry of Health (MOH) of Saudi Arabia declared in an online course with the Healthcare Information and Management Systems Society (HIMSS) that the nation is looking forward to coordinated efforts between nations as this is the vital element for managing the COVID-19 pandemic in the Kingdom of Saudi Arabia (KSA).
In March 2020, the public authorities of the Kingdom of Saudi Arabia (KSA) distributed US$ 675 million in assets for the Strategic Preparedness and Response Plan. All of that money is going toward research, with international organizations providing crisis funding for R&D in order to better understand COVID-19 and accelerate the development of antibodies, diagnostics, and therapeutics.
The MENA biologics & biosimilars market is anticipated to display a CAGR of 3.9% during the conjecture timeframe (2020-2027), attributable to expanding endorsements and dispatches of novel items.
Among item types, the flu antibodies section is projected to hold a significant income share in 2027, attributable to zeroing in on embracing inorganic development procedures among central participants like the arrangement for the foundation of an immunization office. In 2017, Vacsera (Egyvet), an Egyptian organization for veterinary medications and antibodies, signed an agreement with Fabtech Technologies to set up the main immunization office for avian influenza in Cairo, Egypt.
Key companies contributing to the MENA biologics & biosimilars market include Pfizer, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-la Roche Ag, Takeda Pharmaceutical Company Limited, Sanofi S.A., and Amgen, Inc.
Reasons to buy this MENA Biologics & Biosimilars Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging MENA Biologics & Biosimilars Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging MENA Biologics & Biosimilars Market
◘ Leading company profiles reveal details of key MENA Biologics & Biosimilars Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging MENA Biologics & Biosimilars Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 MENA Biologics & Biosimilars Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: MENA Biologics & Biosimilars Industry Impact
Chapter 2 Global MENA Biologics & Biosimilars Competition by Types, Applications, and Top Regions and Countries
2.1 Global MENA Biologics & Biosimilars (Volume and Value) by Type
2.3 Global MENA Biologics & Biosimilars (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global MENA Biologics & Biosimilars Sales, Consumption, Export, Import by Regions
Chapter 5 North America MENA Biologics & Biosimilars Market Analysis
Chapter 6 East Asia MENA Biologics & Biosimilars Market Analysis
Chapter 7 Europe MENA Biologics & Biosimilars Market Analysis
Chapter 8 South Asia MENA Biologics & Biosimilars Market Analysis
Chapter 9 Southeast Asia MENA Biologics & Biosimilars Market Analysis
Chapter 10 Middle East MENA Biologics & Biosimilars Market Analysis
Chapter 11 Africa MENA Biologics & Biosimilars Market Analysis
Chapter 12 Oceania MENA Biologics & Biosimilars Market Analysis
Chapter 13 South America MENA Biologics & Biosimilars Market Analysis
Chapter 14 Company Profiles and Key Figures in MENA Biologics & Biosimilars Business
Chapter 15 Global MENA Biologics & Biosimilars Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027